What changed for Sickle Cell Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Sickle Cell Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 165 to 163 (-2)
- Trials on record 1,001 to 994 (-7)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Sickle Cell Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 133 trials tracked for Sickle Cell Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05714098 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05714098) enrolled 30 participants, all of whom completed the study. There was only one group — everyone took part in an exercise program. The trial was designed as a feasibility study, meaning its main goal was not to test whether the exercise program "worked" in a medical sense, but rather to explore whether it was practical to run, whether participants were willing to stick with it, and whether it was acceptable to those taking part. The reported data shows that 25 out of 30 participants completed at least half of the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05407805 · results posted 10 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05407805) enrolled 98 people with sickle cell disease — 33 in a control group and 65 in a disease-modifying treatment group. The trial was measuring how often participants experienced painful vaso-occlusive crises (VOCs — episodes of severe pain caused by blocked blood flow, a common complication of sickle cell disease). It tracked these events in several ways: through doctor-recorded medical visits, through daily self-reports logged by participants on an electronic app, and through participant-rated scores for pain, tired...
-
NCT04426591 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, 22 people took part in this trial, and all 22 completed it. The trial was studying how long transfused red blood cells (RBCs) survive in the body after being given to a participant. To track the cells, researchers used a harmless vitamin-based label called biotin, which acts like a tag so the transfused cells can be identified and counted in blood samples taken over time. A smaller group of 6 participants also took part in an optional add-on activity that looked at whether a special "pathogen-reduced" blood processing technique — designe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04523376 · results posted 28 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 people in total — 7 with sickle cell disease and 1 with beta thalassemia major. The trial was measuring what happened after participants received a stem cell transplant, specifically looking at whether the transplanted cells successfully "took hold" in the body (called engraftment), whether the body's immune system attacked itself after the transplant (a complication called graft-versus-host disease, or GVHD), and how long it took for white blood cell counts to recover. The reported data shows that in the sickle ce...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05632354 · results posted 19 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05632354) tested a medicine called osivelotor at different doses (100 mg, 150 mg, and 200 mg) in people with a blood condition. Participants were split into two broad groups: those who started the medicine straight away, and those who had a delayed start. A total of 47 people began the trial across all five groups, though the data shows that none of the participants were recorded as having completed the study — all 47 were listed as "not completed." The reported data shows several things were measured as primary outcomes....
-
NCT05451940 · results posted 7 January 2026
According to the results reported on ClinicalTrials.gov, this trial involved 17 participants, all of whom received erythropoietin (a medicine that stimulates the body to produce red blood cells). The trial was measuring whether participants' haemoglobin levels — a measure of red blood cells in the blood — increased after 12 weeks of treatment, and whether the number of blood transfusions they needed changed. One participant did not complete the treatment period, so 16 participants went on to finish the full study including the observation period. The reported data shows that 15 out of 17 part...
-
NCT04930445 · results posted 31 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04930445) enrolled 265 participants, all of whom were in a single group taking a medicine called Oxbryta (voxelotor). The trial was designed to track changes in several blood measurements over up to 60 months (5 years) after starting Oxbryta. These measurements included haemoglobin (a protein in red blood cells that carries oxygen), reticulocytes (young red blood cells, which can indicate how hard the body is working to make new blood cells), bilirubin (a substance produced when red blood cells break down), and ferritin (a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04935879 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04935879) enrolled 241 people — 119 in the inclacumab group and 122 in the placebo group. The trial ran for 48 weeks and was looking at vaso-occlusive crises (VOCs) in people with sickle cell disease. VOCs are sudden, severe pain episodes caused by blocked blood flow, serious enough to require a visit to a medical facility or contact with a healthcare provider for strong pain relief. The trial measured how often these crises occurred, how long it took for the first one to happen, and several other related outcomes. The re...
-
NCT03573882 · results posted 18 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03573882) enrolled 179 people with sickle cell disease across three groups. All participants had previously taken part in an earlier trial (NCT03036813), where they had been assigned to either a placebo, a lower dose (900 mg) of voxelotor, or a higher dose (1,500 mg) of voxelotor. In this follow-on study, the trial was primarily measuring how many participants experienced adverse events (unexpected medical occurrences during the study) — both those considered related to sickle cell disease and those that were not. It also...
-
NCT04170348 · results posted 24 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04170348) enrolled 58 people in total — 27 in a group taking vitamin D3 every day, and 31 in a group taking a larger dose of vitamin D3 once a month. By the end of the study, 22 people in the daily group and 23 in the monthly group had completed it. The trial was primarily measuring how often participants experienced respiratory events (a combined count of chest infections, asthma flare-ups, and a complication called acute chest syndrome) over the course of a year. It also tracked several measures of lung function at the s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05283148 · results posted 24 August 2025
According to the results reported on ClinicalTrials.gov, this study enrolled 53 participants, all of whom completed the study with no drop-outs. The trial was looking at bone density — essentially how strong and dense the bones are — in people with sickle cell disease (SCD) who experience bone pain. Bone density was measured using a special type of low-dose X-ray scan (called a DXA scan) at three sites: the lower spine (lumbar spine), the hip, and the femoral neck (the upper part of the thigh bone where it meets the hip). Participants were split into two groups, referred to as Group A and Grou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02850406 · results posted 15 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02850406) tested a medicine called voxelotor in children and teenagers with sickle cell disease. It was run in four separate parts, each looking at a different age group or dose level. In total, across all parts, 147 young participants took part — 13 in Part A (ages 6–17, short-term dosing), 40 in Part B (adolescents, up to 28 weeks), 62 in Part C (ages 4–17, up to 52 weeks), and 32 in Part D (ages 6 months to under 4 years, up to 52 weeks). Each part had its own main question it was trying to answer. The reported data sh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03938324 · results posted 28 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03938324) enrolled 222 participants in total — 147 in the PiCASO intervention group and 75 in an attention control group (a comparison group that received a different form of contact rather than the main intervention). By the end of the study, 99 participants in the PiCASO group and 53 in the control group had completed the trial. The trial was measuring how people managed their own chronic health conditions over time, looking at things like their knowledge and confidence in managing their health, their readiness to take o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05445128 · results posted 25 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05445128) was studying a treatment approach involving two investigational drugs — MGTA-145 and plerixafor — given to people with sickle cell disease (SCD). The goal was to mobilise and collect a specific type of stem cell (called CD34+ cells) from the blood, which could potentially be used in future cell or gene therapies. The trial had two planned groups: one receiving the drugs over a single day before a blood collection procedure (called apheresis), and a second group receiving the drugs over two days. According to the...
-
NCT05561140 · results posted 9 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05561140) enrolled 88 people in total — 45 in the voxelotor group and 43 in the placebo group — all of whom also received standard of care treatment. The trial was looking at leg ulcers in people with sickle cell disease. The main thing it set out to measure was how many participants had their target ulcer(s) fully healed (defined as complete skin regrowth confirmed at two check-ups two weeks apart) by the 12-week mark. All participants later moved into an open-label phase where everyone received voxelotor, though very few...
-
NCT04218084 · results posted 13 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04218084) enrolled 120 children who received voxelotor and 116 who received a placebo (an inactive treatment used for comparison). Participants were children with sickle cell disease whose brain blood-flow speed — measured using a painless ultrasound scan called transcranial Doppler, or TCD — fell in a "conditional" (borderline elevated) range. The trial's main goal was to see whether voxelotor changed that blood-flow speed over 24 weeks. It is worth noting that a relatively large number of participants did not complete th...
-
NCT04028700 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 participants in total — 3 in one group and 5 in the other. It was a crossover study, meaning participants were planned to receive both types of blood transfusion in sequence, with a four-month "washout" period (a break to let the effects of the first transfusion clear) in between. The trial was comparing two types of donated red blood cells: those from donors with a condition called G6PD deficiency (a common inherited difference in red blood cell chemistry) and those from donors without it. The main thing being meas...
-
NCT03431285 · results posted 28 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 278 adults who came to an emergency department (ED) with pain. They were split into two groups: 140 people received morphine and 138 received ketamine (a different type of pain-relieving medicine). All participants in both groups completed the study. The trial was measuring pain levels over three hours, how long people stayed in the ED, how much opioid (strong pain medicine) was used, how many people needed to be admitted to hospital, and how many people experienced side effects from the medicines. The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03442114 · results posted 25 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03442114) looked at how to support parents of children with sickle cell disease in making decisions about a medication called hydroxyurea. A total of 174 parents took part — 94 were given a tool called the Hydroxyurea Shared Decision Making Toolkit (H-SDM) and 80 received a simpler Clinician Pocket Guide. Of those, 78 and 59 participants respectively completed the study. The trial measured things like how uncertain parents felt about making a treatment decision, how involved they felt in that decision, and how satisfied th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03806452 · results posted 14 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03806452) looked at a medicine called hydroxycarbamide and compared it to a placebo (a dummy treatment with no active ingredient) in people with kidney disease, specifically measuring changes in protein levels in their urine and kidney function over time. In the first phase of the trial, 46 people received hydroxycarbamide and 40 received the placebo. A smaller group of participants who responded to their initial treatment then continued into a second phase — 18 from the hydroxycarbamide group and 15 from the placebo group...
-
NCT02863068 · results posted 7 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 people in total — 10 received a placebo (an inactive treatment) and 8 received a topical sodium nitrite cream applied to their skin ulcers. All 18 participants completed the study. The trial was looking at leg or body ulcers in people with sickle cell disease, and was measuring three main things over 10 weeks: whether methemoglobin levels in the blood changed (methemoglobin is a form of haemoglobin that can rise with certain treatments and is used here as a tolerability marker), whether the total surface area of ul...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04156906 · results posted 2 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 participants, and all 5 completed the study with no one dropping out. The trial was looking at what happens when people who have previously developed an immune response to a blood component called the "D antigen" (known as anti-D) are given red blood cell transfusions that have been carefully matched to their genetic blood type profile. The key question was whether receiving these specially matched blood cells would cause the anti-D immune response to come back, or whether there would be any signs that the transfuse...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04906707 · results posted 20 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04906707) involved 44 adults in total — 19 in the EaseVRx group and 25 in the Active Control group. The trial looked at a virtual reality (VR) program called EaseVRx for people living with chronic pain. It measured self-reported pain levels at regular intervals over eight weeks, as well as how much participants actually used the VR device (engagement). Most participants completed the trial: 16 out of 19 in the EaseVRx group and 24 out of 25 in the Active Control group. The reported data shows that pain was measured using...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03938454 · results posted 10 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 adult male participants, all of whom received infusions of a drug called crizanlizumab at a dose of 5 mg/kg. Thirty participants completed the study, while six did not finish. The trial was looking at a condition called priapism — unwanted or painful erections lasting at least 60 minutes — in people with sickle cell disease. The main thing the researchers were measuring was whether the number of these episodes changed over 26 weeks of treatment. The reported data shows that, on average across participants, the num...
-
NCT04419168 · results posted 19 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04419168) enrolled 359 adults with sickle cell disease — 181 in a group receiving a computer-based cognitive behavioural therapy program (cCBT) and 178 in a group receiving mobile health education (m-Education). By the end of the study, 125 people in each group had completed it fully. The trial was measuring changes over six months in several areas, including how much pain interfered with daily life, daily pain intensity, mood (depression and anxiety), quality of life, and participants' confidence in managing their conditi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04893811 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04893811) looked at a meningococcal B vaccine called Trumenba. It involved two groups: 53 people who received the vaccine as part of this trial (referred to as the B1971060 group), and 51 people whose data came from a previous, similar trial and were used as a historical comparison group (B1971057). Both groups received two doses of the vaccine. The trial measured how the body responded to the vaccine by looking at blood levels of protective antibodies against four strains of the meningococcal B bacteria, and also tracked...
-
NCT02140554 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02140554) enrolled 54 participants across three groups — Group A (9 people), Group B (2 people), and Group C (43 people). The trial was measuring the effects of a treatment called lovo-cel, given via an infusion, in people with sickle cell disease. The main focus was on Group C, and the key thing being measured was whether participants experienced a complete stop in painful crisis episodes — known as vaso-occlusive events (VOEs), which are episodes where blood flow is blocked, causing severe pain — during the period betwee...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03593395 · results posted 3 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03593395) enrolled people with sickle cell disease who were moving from childhood to adult healthcare — a process called "transition." A total of 291 participants were enrolled across two groups: 196 people received a structured education-based transition program, and 95 people received that same program plus peer mentoring (support from someone with lived experience of the same condition). By the end of the study, 121 people in the first group and 49 in the second group had completed participation. The reported data show...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01443728 · results posted 9 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 62 people in total — 31 in a higher-dose vitamin D3 group (100,000 IU) and 31 in a lower-dose group (12,000 IU). Of those, 28 people in each group completed the study, with 3 in each group not finishing. The trial was measuring whether the dose of vitamin D3 made a difference to the number of breathing-related health events participants experienced, such as respiratory infections, asthma flare-ups, and a condition called acute chest syndrome. It also tracked vitamin D levels in the blood and several measures of lung f...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01891812 · results posted 16 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT01891812) enrolled 5 participants who received nitrous oxide (sometimes called "laughing gas") as a form of pain relief. The trial was set up to measure how much pain participants felt right after receiving the nitrous oxide, how long the pain relief lasted before they needed something extra, and whether any participants developed certain side effects — specifically nerve-related symptoms or a type of anaemia (low red blood cell count) linked to low vitamin B12 levels. Notably, the reported data shows that none of the 5 pa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 133 reported results for Sickle Cell Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is currently directed toward Sickle Cell Disease, and the level of that funding has remained broadly steady from year to year. This consistency suggests that Sickle Cell Disease is an established research priority rather than a newly emerging or fading area of interest. For patients, a stable and substantial funding bas...
See the full Sickle Cell Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.